Movement disorder

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial

Retrieved on: 
星期二, 三月 14, 2023
Emerald, Disease, Bluerock Creek, HIV disease progression rates, Research, Medicine, Apple, Apple Watch, Parkinson's disease, Artificial intelligence, Data collection, Collaboration, Patient, Bayer, Therapy, Trial of the century, Tremor, Dyskinesia, Drug development, Labs, Rigidity, Movement disorder, Radio, Medical imaging, Pharmaceutical industry

CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.

Key Points: 
  • Rune Labs' StriveStudy platform and Emerald Innovations' Emerald wireless monitoring sensor will passively capture data on Parkinson's disease impact on function of fifty study participants in BlueRock's global non-interventional clinical study.
  • CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned, independently operated subsidiary of Bayer AG, today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson's disease clinical trials.
  • Emerald Innovations' Emerald monitoring biosensor belongs to a new class of sensors called "invisibles" that extract health metrics from radio signals, without wearable devices.
  • Our collaboration with BlueRock enables a data-driven clinical trial in Parkinson's while patients go about their normal lives," said Dr. Dina Katabi, Co-Founder of Emerald Innovations.

Highlights Revealed for 8th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress

Retrieved on: 
星期三, 三月 8, 2023
DSM-IV codes, Physician, Science, Parkinson's disease, Research, Disease, CDT, APPA, Education, Patient, Deep brain stimulation, Parkinson, Movement, Conference, Abstract, Movement disorder, Dentistry, Pharmaceutical industry

KOLKATA, India, March 7, 2023 /PRNewswire-PRWeb/ -- The 8th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC) will feature breaking research and education in the quickly evolving field of Movement Disorders from March 17-20 at the ITC Royal Bengal Hotel in Kolkata, India.

Key Points: 
  • The 8th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC) will feature breaking research and education in the quickly evolving field of Movement Disorders.
  • KOLKATA, India, March 7, 2023 /PRNewswire-PRWeb/ -- The 8th Asian and Oceanian Parkinson's Disease and Movement Disorders Congress (AOPMC) will feature breaking research and education in the quickly evolving field of Movement Disorders from March 17-20 at the ITC Royal Bengal Hotel in Kolkata, India.
  • The bi-annual event focuses on disease features that are specific to Asia and Oceania, bringing together clinical, research and health professional leaders to collaborate and share ideas that advance movement disorders science and care across the region.
  • The Movement Disorders Society of India's 7th annual MDSICON will be the preceding day, Thursday, March 16.

TSC Alliance® to Present 22nd Annual Comedy for a Cure® on April 2

Retrieved on: 
星期四, 三月 2, 2023
Courage, DSM-IV codes, Comedy, Russell Peters, Ramesh, Avalon Hollywood, Jazz Pharmaceuticals, Research, Neoplasm, Last Comic Standing (season 4), Ovation, Global Leadership Awards, Investment, Cure, Movement disorder, Maginn, Disease, Lesley, TSC, NBC, Film industry, Pharmaceutical industry, Entertainment, Epilepsy

LOS ANGELES, March 2, 2023 /PRNewswire/ -- Today, the TSC Alliance® announced its 22nd Annual Comedy for a Cure® will be held Sunday, April 2, at AVALON Hollywood. The event brings together top comedians and entertainers to raise funds for those impacted by tuberous sclerosis complex (TSC), a rare genetic disease that causes tumors to form in vital organs.

Key Points: 
  • LOS ANGELES, March 2, 2023 /PRNewswire/ -- Today, the TSC Alliance ® announced its 22nd Annual Comedy for a Cure ® will be held Sunday, April 2, at AVALON Hollywood .
  • "Since its inception, the TSC Alliance's national signature event, Comedy for a Cure, has raised more than $5.5 million toward finding a cure for TSC while improving the lives of those affected," said Kari Luther Rosbeck, President & CEO.
  • We are proud to support the TSC Alliance's Comedy for a Cure, which emphasizes this mindset shared by Jazz."
  • Comedy for a Cure also provides a platform to highlight and pay tribute to those who have made an impact in the fight against TSC.

Europe Home Healthcare Market Report 2022: Cost-Effectiveness and Comfort Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
星期二, 一月 31, 2023
Managed Care, Health, Respiratory therapist, Palliative care, Abbott Laboratories, Life expectancy, Country, ResMed, Invacare, Patient, Therapeutic Products Directorate, Movement disorder, Product type, Hospice, Huber loss, Person, Hypertension, Omron, Hospice Palliative Care Ontario, Policy, Diabetes, Nursing, Linde plc, Service, Hospital, Mental health, Pregnancy, Cancer, EU, Limited

The "Europe Home Healthcare Market Size, Share & Industry Trends Analysis Report By Type (Services and Product), By Indication, By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Home Healthcare Market Size, Share & Industry Trends Analysis Report By Type (Services and Product), By Indication, By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The home healthcare market is expected to expand in the Europe area over the next years as a result of all these factors.
  • The Germany market dominated the Europe Home Healthcare Market by Country in 2021; thereby, achieving a market value of $26, 194.4 million by 2028.
  • The market research report covers the analysis of key stake holders of the market.

Memorial Neurosurgery Team First in South Florida to Perform Robotic-Assisted "Asleep" Deep Brain Stimulation to Treat Parkinson's Disease

Retrieved on: 
星期一, 二月 20, 2023
Neurosurgery, Electrode, Brain, Neurology, Patient, CT, Safety, Movement disorder, Tremor, ZEUS robotic surgical system, Skin, ROSA, DBS, DSM-IV codes, Parkinson's disease, Deep brain stimulation, Dystonia, Medical device, Nursing

HOLLYWOOD, Fla., Feb. 20, 2023 /PRNewswire-PRWeb/ -- Deep brain stimulation (DBS) is a proven surgical treatment where a neurosurgeon implants electrodes in a specific area of the brain to help relieve tremors and symptoms of stiffness and slowness in patients who have Parkinson's disease or another movement disorder, such as dystonia. However, traditional DBS surgery can be unpleasant and painful, as it is performed while the patient is awake and requires individuals to stop taking any medications to control their movement disorders.

Key Points: 
  • Memorial Neuroscience Institute is the first in South Florida to offer an advanced method of DBS that is performed while the patient is comfortably asleep under general anesthesia.
  • "Our team of neurologists, neuropsychologists and neurosurgeons perform a detailed evaluation of each patient to determine their care plan," said Dr. Harsh Gupta, neurologist who specializes in movement disorders at Memorial Neuroscience Institute.
  • Patients who want to learn more about DBS should speak with their neurologist or primary care physician who may refer them to Memorial Neuroscience Institute.
  • To learn more about Memorial Neuroscience Institute, visit http://www.mhs.net/neuroscience or call 954-265-9500.

Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved

Retrieved on: 
星期三, 二月 1, 2023
Artificiality, Medical device, Deep learning, Physician, Neurology, Human, ICP, Diagnosis, V-Moda, Safety, Drug development, Movement disorder, Patient, Software, Ageing, Research, Therapy, DSM-IV codes, Intelligence, Movement, X-ray, Information technology, National Medical Products Administration, Digital, Parkinson's disease, Surgeon, AI, Classification, Medical imaging, Pharmaceutical industry

WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other movement disorders, has been approved by the China National Medical Products Administration, making it the first video-based AI-powered medical device for the assessment of movement disorders.

Key Points: 
  • WUHAN, China, Feb. 1, 2023 /PRNewswire/ -- NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other movement disorders, has been approved by the China National Medical Products Administration, making it the first video-based AI-powered medical device for the assessment of movement disorders.
  • MoDAS uses consumer-level smart mobile devices to conveniently capture video of the patient's movement status.
  • No adverse events were observed in patients in this study, demonstrating excellent safety and efficacy.
  • "Information technology, after more than 50 years of development, has proven its power and value to all of humanity.

INSIGHTEC ANNOUNCES POSITIVE COVERAGE DECISION BY CIGNA FOR FOCUSED ULTRASOUND TO TREAT ESSENTIAL TREMOR

Retrieved on: 
星期二, 一月 31, 2023
Blue Cross Blue Shield Association, Anthem, Medicare, Insightec, Essential tremor, Health, Neuro, Aetna, Movement disorder, Patient, Tremor, Health insurance, Cigna

HAIFA, Israel & MIAMI, Jan. 31, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that Cigna is the fourth national payor to cover focused ultrasound for treating medication-refractory essential tremor.

Key Points: 
  • HAIFA, Israel & MIAMI, Jan. 31, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that Cigna is the fourth national payor to cover focused ultrasound for treating medication-refractory essential tremor.
  • "We are so excited to have another national payor providing access to focused ultrasound to non-Medicare patients," said Dee Kolanek, Insightec Vice President of Market Access and Reimbursement.
  • "We want to extend our thanks to leading insurers like Cigna for their decision to cover this game-changing outpatient treatment for essential tremor patients."
  • Focused ultrasound treatment for medication-refractory essential tremor is covered by Medicare in all 50 states.